245487-45-0

Usage

Uses

Used in Pharmaceutical Industry:
2,2,2-Trifluoro-1-(piperazin-1-yl)ethanone hydrochloride is used as an intermediate for the manufacture of antihistamines, antidepressants, and other pharmaceutical products. Its unique structure and reactivity contribute to the development of these medications, enhancing their efficacy and therapeutic potential.
Used in Agrochemical Industry:
In the agrochemical sector, 2,2,2-trifluoro-1-(piperazin-1-yl)ethanone hydrochloride is utilized as a precursor in the synthesis of various agrochemicals, playing a crucial role in the development of products that protect crops and enhance agricultural yields.
Used as a Research Reagent:
2,2,2-Trifluoro-1-(piperazin-1-yl)ethanone hydrochloride also serves as a research reagent in both laboratory and industrial settings. Its versatility and reactivity make it an essential tool for scientists and researchers working on the development of new chemical compounds and processes.

Upstream product

• 914361-73-2 1-trifluoroacetyl-4-trityl piperazine 
• 77278-37-6 4-(2,2,2-trifluoroacetyl)piperazine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF MIRNA BIOGENESIS

The present disclosure relates to compounds and methods for inhibiting the formation of miRNAs that inhibit translation of one or more identified proteins. The compounds comprise antisense oligonucleotides targeting the ph-miRNA precursor of miRNAs.

ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING FOOT AND MOUTH DISEASE

An antiviral antisense composition and method for treating foot-and-mouth disease virus (FMDV) in veterinary animals is disclosed. The composition contains an antisense compound that has a sequence effective to target at least 12 contiguous bases of an FM

Multimeric VLA-4 antagonists comprising polymer moieties

Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

POLYETHYLENE GLYCOL CONJUGATES OF HETEROCYCLOALKYL CARBOXAMIDO PROPANOIC ACIDS

Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e